How do next generation sequencing platforms differ from sanger sequencing in thr

Updated 9/5/2025

Next-generation sequencing (NGS) platforms differ from Sanger sequencing primarily in their throughput, read length, and applications, with NGS enabling high-throughput sequencing of multiple fragments simultaneously, while Sanger sequencing is limited to single-fragment processing.

Why it matters

How to apply

  1. Select the Appropriate Platform: Choose an NGS platform based on the project requirements (e.g., Illumina for short reads, PacBio or Oxford Nanopore for long reads).
  2. Sample Preparation: Follow specific protocols for library preparation, ensuring quality control of the DNA or RNA samples.
  3. Sequencing: Run the samples on the chosen NGS platform, adhering to manufacturer guidelines for optimal performance.
  4. Data Analysis: Utilize bioinformatics tools to process raw sequencing data, including quality control, alignment, variant calling, and functional annotation.
  5. Interpret Results: Collaborate with bioinformaticians and domain experts to interpret the data in the context of the biological question being addressed.
  6. Validation: Consider validating key findings using Sanger sequencing or other methods to confirm results, especially for clinical applications.

Metrics to track

Pitfalls

Key takeaway: NGS offers significant advantages over Sanger sequencing in throughput and application scope, but it requires careful planning and expertise in data analysis.